|
市場調查報告書
治療更年期障礙的良機：新治療法能否超越賀爾蒙補充療法
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement?
|
治療更年期障礙的良機：新治療法能否超越賀爾蒙補充療法 是由出版商Decision Resources, Inc.在2009年06月所出版的。
這份英文市場調查報告書包含37 Pages 價格從美金3450起跳。
數十年來，治療更年期障礙多以賀爾蒙補充療法為主，但此療法中含有動情激素，在安全性方面仍有疑慮，因此研究人員與製藥業正著手進行新治療機制之研究。
本報告整理了更年期障礙概述與目前的治療方法、新興的治療方法、2008年市場的動向與未來展望等主題，其內容大略如下所示。
實施概要
前言
更年期障礙之概述
- 定義與說明
- 更年期障礙的症狀
- 血管舒縮症狀（Vasomotor Symptoms）
- 增加罹患心血管疾病之風險
- 失眠
- 憂鬱
- 其他症狀
目前因應更年期障礙的治療方法
- 賀爾蒙補充療法
- 選擇性動情激素受體調節劑
- 選擇性血清素再吸收抑制或雙重再吸收抑制劑（Serotonin and Norepinephrine Reuptake Inhibitors）
- 加巴噴丁（Gabapentin）
- 其他
新興的治療藥物
- 惠氏 Pristiq
- 惠氏骨質疏鬆藥物Bazedoxifene與組合態動情激素之結合使用
- Depomed' s Gabapentin
- Schering-Plough' s Esmirtazapine
更年期障礙市場之未來展望
表
- 賀爾蒙補充療法之品牌
- 選擇性血清素再吸收抑制或雙重再吸收抑制劑（Serotonin and Norepinephrine Reuptake Inhibitors）
- 治療更年期障礙之新藥
- 治療更年期障礙藥物之銷售額：2008年
圖
- 內分泌變化與更年期障礙之關聯
- 全世界賀爾蒙補充療法之銷售額：2003∼2008年
Abstract
Introduction
For decades, the efficacy of hormone replacement therapy (HRT) for some of
menopause' s most troublesome symptoms eliminated any incentive to develop new
approaches to treatment. However, data questioning the safety of
estrogen-containing therapies have galvanized researchers and drug developers
to begin investigating new mechanisms to treat menopausal symptoms that can
capitalize on the newly realized need for safer treatment options, although
these agents will still be challenged by the efficacy of HRTs.
Questions Answered in This Report
- Menopause is a natural process of aging that is accompanied by substantial
hormonal changes. What are the symptoms of menopause? What are the causes of
these symptoms? What are the current treatment options? What are the benefits
and drawbacks of these treatments?
- Data from the Women' s Health Initiative suggest that estrogen therapy is
not suitable for all women. What are the risks associated with hormone
therapy? Do emerging agents offer safer or more efficacious treatment
approaches?
- With the final wave of baby boomers reaching menopausal age, the
menopause treatment patient population is on the rise. What were the sales of
menopausal symptom treatments in 2008? How well will emerging agents address
the remaining needs in this market? How will emerging agents fit into the
treatment algorithm in the future?
Scope
- Overview of menopause: Physiology and symptoms.
- Current treatments: Hormone replacement therapy, selective estrogen
receptor modulators, SSRIs/SNRIs, gabapentin.
- Emerging treatments: Wyeth' s Pristiq, Wyeth' s bazedoxifene/conjugated
estrogens, Depomed' s controlled-release gabapentin, Schering-Plough' s
esmirtazapine.
- Outlook: 2008 market, challenges and opportunities, the potential of
emerging agents, the future of HRT.
- Women' s Health Series: This report is part of Spectrum' s Women' s Health
Series, which focuses on areas of unmet need and the best marketing strategies
to ensure adoption of a new agent into the market for women' s reproductive
health - a sector that exceeded $23 billion in 2007.
Mentioned in This Report
Companies
- Bayer-Schering
- Bionovo
- Boehringer Ingelheim
- Chugai
- Concert Pharmaceuticals
- Depomed
- Eli Lilly
- Forest
- GlaxoSmithKline
- Novartis
- Novo Nordisk
- Pfizer
- Radius
- Schering-Plough
- Solvay
- Wyeth
Table of Contents
Contents
Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Overview of Menopause
- Definition and Description
- Symptoms of Menopause
- Vasomotor Symptoms
- Osteoporosis
- Increased Cardiovascular Disease Risk
- Insomnia
- Depression
- Other Symptoms
Current Treatments for Menopausal Symptoms
- Hormone Replacement Therapy
- Selective Estrogen Receptor Modulators
- Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine
Reuptake Inhibitors
- Gabapentin
- Other Treatments
Emerging Treatments for Menopausal Symptoms
- Wyeth' s Pristiq
- Wyeth' s Bazedoxifene/Conjugated Estrogen Combination
- Depomed' s Gabapentin
- Schering-Plough' s Esmirtazapine
Outlook for the Menopausal Symptom Market
Tables
- 1. Common Brands of Hormone Replacement Therapy
- 2. Common Selective Serotonin Reuptake Inhibitors and Serotonin and
Norepinephrine Reuptake Inhibitors
- 3. Emerging Agents for the Treatment of Menopausal Symptoms
- 4. Sales of Agents to Treat Menopausal Symptoms, 2008
Figures
- 1. Endocrine Changes Associated with Menopause
- 2. Worldwide Sales of Hormone Replacement Therapy, 2003-2008
|
